Hospital Universitario Quiron-Dexeus

Barcelona 08028

1 studies enrolling now · 7 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Breast Cancer, Cancer, Early Breast Cancer, Low Back Pain, Non-Small-Cell Lung Carcinoma, Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Studies at this site

• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors — Recruiting now
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed
• Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations — Stopped early
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain — Completed
• A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment — Completed